← Back to Search

Nipple Aspirate Fluid Detection for Breast Cancer

N/A
Recruiting
Led By William Carson, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BREAST CANCER: Must be > 1 year from pregnancy, lactation.
BREAST CANCER: Must be currently diagnosed with known breast cancer in breast.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is looking into whether or not nipple aspirate fluid can help detect breast cancer earlier on than other methods such as mammograms or breast examinations.

Who is the study for?
This trial is for women over a year removed from pregnancy or lactation, with current breast cancer diagnosis or healthy subjects without any cancer. Healthy participants must have had a recent non-suspicious breast exam/mammogram. Exclusions include men, those pregnant/lactating within the last year, and anyone with cancers other than breast.Check my eligibility
What is being tested?
The study is examining nipple aspirate fluid to see if it's more effective at early detection of breast cancer compared to traditional screening methods like mammograms and clinical exams.See study design
What are the potential side effects?
Since this trial involves collecting fluid samples and not testing a drug or therapy, there are minimal side effects expected beyond potential discomfort or bruising from the aspiration procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must be more than 1 year past your last pregnancy or breastfeeding.
Select...
You must currently have been diagnosed with breast cancer in the breast.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biomarkers expression levels

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (nipple aspiration fluid)Experimental Treatment2 Interventions
Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1920

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,607 Previous Clinical Trials
40,913,884 Total Patients Enrolled
939 Trials studying Breast Cancer
1,543,333 Patients Enrolled for Breast Cancer
Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,586 Total Patients Enrolled
22 Trials studying Breast Cancer
2,884 Patients Enrolled for Breast Cancer
William Carson, MD4.86 ReviewsPrincipal Investigator - Ohio State University Comprehensive Cancer Center
5 Previous Clinical Trials
154 Total Patients Enrolled
1 Trials studying Breast Cancer
99 Patients Enrolled for Breast Cancer
5Patient Review
I couldn't have been more pleased.

Media Library

Aspiration of Breast 2023 Treatment Timeline for Medical Study. Trial Name: NCT03715959 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities yet to join this research endeavor?

"Affirmative, the information on clinicaltrials.gov indicates that this research is actively enrolling volunteers. The study was initially posted on July 25th 2019 and most recently revised on November 6th 2022. This investigation requires 100 participants from a single medical centre."

Answered by AI

To what extent is this research study populated with participants?

"Affirmative. According to the clinicaltrials.gov portal, this clinical study is presently recruiting patients who initially posted on July 25th 2019 and last updated on November 6th 2022. This trial requires 100 individuals from 1 location for enrollment purposes."

Answered by AI

Who else is applying?

What site did they apply to?
Ohio State University Comprehensive Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
~18 spots leftby Mar 2025